These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24934346)

  • 1. DNA binding mode of transition metal complexes, a relationship to tumor cell toxicity.
    Ashfaq M; Najam T; Shah SS; Ahmad MM; Shaheen S; Tabassum R; Rivera G
    Curr Med Chem; 2014; 21(26):3081-94. PubMed ID: 24934346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copper compounds in cancer chemotherapy.
    Ruiz-Azuara L; Bravo-Gómez ME
    Curr Med Chem; 2010; 17(31):3606-15. PubMed ID: 20846116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
    Liu W; Gust R
    Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent development of transition metal complexes with in vivo antitumor activity.
    Liang JX; Zhong HJ; Yang G; Vellaisamy K; Ma DL; Leung CH
    J Inorg Biochem; 2017 Dec; 177():276-286. PubMed ID: 28641893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cancer property and DNA binding interaction of first row transition metal complexes: A decade update.
    Dasmahapatra U; Maiti B; Alam MM; Chanda K
    Eur J Med Chem; 2024 Sep; 275():116603. PubMed ID: 38936150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Good Fashion is Evolution, Not Revolution" - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal.
    Guzowska M; Kalinowska M; Lewandowski W
    Anticancer Agents Med Chem; 2018; 18(4):476-487. PubMed ID: 29189181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition metals and metal complexes in autophagy and diseases.
    Luo Y; Fu Y; Huang Z; Li M
    J Cell Physiol; 2021 Oct; 236(10):7144-7158. PubMed ID: 33694161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition Metal Intercalators as Anticancer Agents-Recent Advances.
    Deo KM; Pages BJ; Ang DL; Gordon CP; Aldrich-Wright JR
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27809241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
    Babak MV; Ang WH
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation anticancer metallodrugs.
    Komeda S; Casini A
    Curr Top Med Chem; 2012; 12(3):219-35. PubMed ID: 22236158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo.
    Ma J; Yang X; Hao W; Huang Z; Wang X; Wang PG
    Eur J Med Chem; 2017 Mar; 128():45-55. PubMed ID: 28147308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies.
    Adhikari S; Nath P; Das A; Datta A; Baildya N; Duttaroy AK; Pathak S
    Biomed Pharmacother; 2024 Feb; 171():116211. PubMed ID: 38290253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions.
    Riddell IA
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Metallodrugs that Target Proteins.
    Sullivan MP; Holtkamp HU; Hartinger CG
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.
    Zaludová R; Natile G; Brabec V
    Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, interaction with DNA and bovine serum albumin of the transition metal complexes of demethylcantharate and 2-aminobenzothiazole.
    Zhang F; Lin QY; Li SK; Zhao YL; Wang PP; Chen MM
    Spectrochim Acta A Mol Biomol Spectrosc; 2012 Dec; 98():436-43. PubMed ID: 22995471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate-metal complexes and their potential as anticancer agents.
    Hartinger CG; Nazarov AA; Ashraf SM; Dyson PJ; Keppler BK
    Curr Med Chem; 2008; 15(25):2574-91. PubMed ID: 18855680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.